Literature DB >> 7165313

Intraindividual variations of 8-methoxypsoralen plasma levels.

M Schäfer-Korting, H C Korting.   

Abstract

Intraindividual variations of 8-methoxypsoralen (8-MOP) plasma levels were investigated. On at least 3 consecutive days of treatment 8-MOP levels were determined 2 h following the administration of 0.56-0.82 mg/kg b.w. On day 1 a complete plasma level-time profile was obtained. Interindividually, 8-MOP plasma levels varied from 0-654 ng/ml. Intraindividual variation was considerably less being 1.2-5.3-fold. In one patient who showed a lower absorption rate of 8-MOP plasma levels varied from 0-126 ng/ml. There was a rather close correlation (r = 0.81) of the variation of 8-MOP plasma levels (determined as the ratio of highest to lowest plasma level) and mean plasma level, intraindividual variation decreasing exponentially with increasing 8-MOP plasma levels. Parameters determining variation of 8-MOP plasma levels are the intrinsic hepatic clearance, liver blood flow, and possibly the absorption of the drug from gastrointestinal tract. To keep intraindividual variation as low as possible ingestion of the drug together with a standardized meal is suggested. Drugs interfering with hepatic metabolism or liver blood flow should be avoided.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7165313     DOI: 10.1007/bf00510387

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  26 in total

1.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

2.  Intraindividual variation in drug disposition.

Authors:  A P Alvares; A Kappas; J L Eiseman; K E Anderson; C B Pantuck; E J Pantuck; K C Hsiao; W A Garland; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

3.  A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents.

Authors:  M S Sasaki; A Tonomura
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

4.  Improved delivery of methoxsalen.

Authors:  J Kreuter; T Higuchi
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

5.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

6.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

7.  Photochemotherapy for psoriasis.

Authors:  H H Roenigk; J S Martin
Journal:  Arch Dermatol       Date:  1977-12

8.  Plasma levels of 8-methoxypsoralen determined by high-pressure liquid chromatography in psoriatic patients ingesting drug from two manufacturers.

Authors:  B Ljunggren; D M Carter; J Albert; T Reid
Journal:  J Invest Dermatol       Date:  1980-01       Impact factor: 8.551

9.  Photochemotherapy of psoriasis with relevance to 8-methoxypsoralen plasma level and low intensity irradiation.

Authors:  P Thune; G Volden
Journal:  Acta Derm Venereol       Date:  1977       Impact factor: 4.437

10.  Pharmacokinetic and clinical comparison of two 8-methoxypsoralen brands.

Authors:  K E Andersen; T Menne; M Gammeltoft; N Hjorth; E Larsen; P Solgaard
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

View more
  2 in total

1.  Variations in skin photosensitization during repeated oral 8-methoxypsoralen medication.

Authors:  C T Jansén; G Wilén; R Paul
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 2.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.